ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

This is a non-randomized controlled trial to compare the outcome of immune tolerance induction therapy usingnon- SCT800 combined with Daratumumab or SCT800 alone in hemophilia A adolescents and adults with high titer inhibitors. Patients will receive Daratumumab combined with SCT800 or SCT800 alone.

Inclusion criteria

• Moderate or severe hemophilia A;
• Aged 14-66 years old;
• Inhibitor positive at 2 consecutive visits;
• Inhibitor titer > 10 BU at the screening visit.

Exclusion criteria

• The patient has contraindications to drug ingredients or hamster protein allergy;
• Suffering from other immune diseases or Using immunosuppressant IS to treat another disease(s);
• Failed systemic ITI treatment in history;
• Poor patients compliance;
• The investigator believes that there are any other reasons that make the patient unsuitable to participate in this study.